Results 1 to 10 of about 10,563 (118)

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry [PDF]

Viruses
Background: Data on the use of dolutegravir (DTG) plus boosted darunavir (DRV/b) in people with 4-class drug-resistant HIV (4DR-PWH) are limited. This study assessed the virological effectiveness of DTG + DRV/b in this population using real-world data ...
Filippo Lagi, Michele Bellomo, Riccardo Lolatto, Filippo Ducci, Seble Tekle Kiros, Vincenzo Spagnuolo, Rebecka Papaioannu Borjesson, Tommaso Clemente, Leonardo Calza, Marcello Feasi, Emanuele Focà, Andrea Giacomelli, Roberto Gulminetti, Barbara Menzaghi, Antonella Castagna, on behalf of the PRESTIGIO Study Group   +15 more
doaj   +2 more sources

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Viruses, 2023
Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def.
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto   +15 more
doaj   +1 more source

Mild self-declared side effects of boosted darunavir associated with other antiretrovirals in Romanian HIV-1 infected patients [PDF]

Archives of the Balkan Medical Union, 2021
Introduction. Antiretroviral therapy (ART) is used in human immunodeficiency virus (HIV)-infected patients, to suppress viral replication and slow disease progression.
Ruxandra C. MARIN, Adrian STREINU-CERCEL, Simona BUNGAU   +2 more
doaj   +1 more source

Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?

Children, 2022
Children on antiretroviral therapy have limited options, particularly if they are failing therapy and live in resource-poor settings. We describe three cases where children accessed third-line antiretroviral therapy off-label, or used them ...
Lisa Jane Frigati, Helena Rabie
doaj   +1 more source

Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database

Scientific Reports, 2021
This current investigation was aimed to generate signals for adverse events (AEs) of darunavir-containing agents by data mining using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Xiaojiang Tian, Yao Yao, Guanglin He, Yuntao Jia, Kejing Wang, Lin Chen   +5 more
doaj   +1 more source

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients

Biomedicines, 2021
The management of the side effects caused by the antiretroviral therapy is one of the main problems facing clinicians. The patient’s tolerability and safety influence the success of the therapy.
Ruxandra-Cristina Marin, Delia Mirela Tiț, Oana Săndulescu, Adrian Streinu-Cercel, Simona Gabriela Bungău   +4 more
doaj   +1 more source

Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines

Scientific Reports, 2021
The intracellular penetration of darunavir, a second-generation HIV protease inhibitor, is limited by the activity of the efflux P-glycoprotein (ABCB1).
Gabriel Stillemans, Happy Phanio Djokoto, Kévin-Alexandre Delongie, Halima El-Hamdaoui, Nadtha Panin, Vincent Haufroid, Laure Elens   +6 more
doaj   +1 more source

Promising COVID-19 therapies on examples of some antiviral, immunomodulatory and natural substances use - review

Journal of Education, Health and Sport, 2022
COVID-19 is one of the biggest challenges to medicine ever. Because of its dissemination in population effective drug to cure it was needed. There were some trials on antiviral drugs like lopiravir/ritonavir, remdesivir, darunavir/cobicistat ...
Krzysztof Bielewicz, Karolina Ryba, Anna Karaś, Kinga Kawałko, Kamil Pondel   +4 more
doaj   +1 more source

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

HIV Research & Clinical Practice, 2020
Background The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. Objective To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based ...
Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong   +5 more
doaj   +1 more source

Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model

Pharmaceutics, 2022
Modulation of drug transporter activity at mucosal sites of HIV-1 transmission may be exploited to optimize retention of therapeutic antiretroviral drug concentrations at target submucosal CD4+ T cells.
Constandinos Carserides, Kieron Smith, Marta Zinicola, Abhinav Kumar, Magda Swedrowska, Carlo Scala, Gary Cameron, Zoe Riches, Francesco Iannelli, Gianni Pozzi, Georgina L. Hold, Ben Forbes, Charles Kelly, Karolin Hijazi   +13 more
doaj   +1 more source